Bare Escentuals plans stock sale
This article was originally published in The Rose Sheet
Executive Summary
Firm is offering 8 mil. shares at an initial price of $36.50 apiece to raise $2.9 mil. in funds to be used for "general corporate purposes and working capital," Bare Escentuals announces June 14. The company itself will sell 100,000 shares; the remaining 7.9 mil. will be sold by shareholders, including members of Bare Escentuals' management. The sale will reduce Berkshire Partners LLC's stake in the firm from 29.9% to 25.5% and JH Partners LLC's interest from 14% to 11.9%. Goldman Sachs is the lead underwriter for the offering, and some stockholders have offered the underwriters an option to purchase up to 1.2 mil. additional shares...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.